Stock listing
NYSE American:SER Serina Therapeutics, Inc. Stock
Home listing (NYSE American) of Serina Therapeutics, Inc.
Follow Serina Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · AMEX:SER
$1.12 USD -0.23 (-17.0%)
Close on Nov 20, 2026
- Day range
- $1.06 – $1.26 USDNov 20, 2026
- Volume
- 62,151 sharesNov 20, 2026
- Market cap
- $28.45M USDAt the close on Nov 20, 2026 · price × 25.40M shares outstanding
- 52-week range
- $1.06 – $4.26 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $134,681 USDMedian day 31,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:SER · Home | $1.12 USD | -0.23 (-17.0%) | 62,151 | $1.16 | $1.26 | $1.06 | $1.35 | Close on Nov 20, 2026 |
| Frankfurt:2BO | €1.06 EUR | -0.14 (-11.7%) | — | €1.07 | €1.07 | €1.06 | €1.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:SER · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.12 | -0.23 | -17.0% | $1.16 | $1.26 | $1.06 | 62,151 | |
| $1.35 | -0.015 | -1.1% | $1.46 | $1.46 | $1.35 | 12,204 | |
| $1.365 | -0.055 | -3.9% | $1.32 | $1.41 | $1.30 | 28,434 | |
| $1.42 | +0.03 | +2.2% | $1.41 | $1.45 | $1.34 | 56,667 | |
| $1.39 | -0.02 | -1.4% | $1.35 | $1.52 | $1.35 | 10,774 | |
| $1.41 | -0.09 | -6.0% | $1.50 | $1.555 | $1.39 | 28,386 | |
| $1.50 | +0.07 | +4.9% | $1.46 | $1.614 | $1.42 | 17,879 | |
| $1.43 | 0.00 | 0.0% | $1.43 | $1.53 | $1.39 | 44,578 | |
| $1.43 | +0.05 | +3.6% | $1.29 | $1.54 | $1.29 | 91,788 | |
| $1.38 | -0.27 | -16.4% | $1.65 | $1.713 | $1.14 | 491,717 | |
| $1.65 | -0.04 | -2.4% | $1.68 | $1.709 | $1.614 | 21,200 | |
| $1.69 | -0.14 | -7.7% | $1.70 | $1.80 | $1.626 | 39,627 | |
| $1.83 | -0.02 | -1.1% | $1.79 | $1.85 | $1.67 | 30,588 | |
| $1.85 | -0.09 | -4.6% | $1.92 | $1.99 | $1.85 | 37,818 | |
| $1.94 | +0.05 | +2.6% | $1.47 | $2.55 | $1.47 | 155,099 | |
| $1.89 | +0.25 | +15.2% | $1.51 | $1.99 | $1.485 | 60,508 | |
| $1.64 | -0.03 | -1.8% | $1.28 | $1.70 | $1.28 | 28,260 | |
| $1.67 | -0.04 | -2.3% | $1.38 | $1.75 | $1.38 | 172,032 | |
| $1.71 | +0.06 | +3.6% | $1.63 | $1.75 | $1.588 | 38,290 | |
| $1.65 | -0.11 | -6.3% | $1.73 | $1.76 | $1.65 | 8,000 | |
| $1.76 | -0.01 | -0.6% | $1.73 | $1.80 | $1.72 | 51,300 | |
| $1.77 | +0.11 | +6.6% | $1.67 | $1.78 | $1.63 | 39,800 | |
| $1.66 | +0.01 | +0.6% | $1.64 | $1.735 | $1.63 | 42,100 | |
| $1.65 | -0.07 | -4.1% | $1.75 | $1.81 | $1.65 | 22,000 | |
| $1.72 | -0.07 | -3.9% | $1.72 | $1.83 | $1.72 | 15,700 | |
| $1.79 | +0.08 | +4.7% | $1.71 | $1.94 | $1.71 | 27,400 | |
| $1.71 | -0.11 | -6.0% | $1.80 | $1.838 | $1.71 | 46,300 | |
| $1.82 | -0.12 | -6.2% | $1.92 | $1.974 | $1.78 | 26,300 | |
| $1.94 | -0.06 | -3.0% | $2.01 | $2.01 | $1.90 | 132,200 | |
| $2.00 | -0.01 | -0.5% | $1.99 | $2.05 | $1.99 | 22,300 | |
| $2.01 | 0.00 | 0.0% | $2.01 | $2.05 | $1.99 | 59,300 | |
| $2.01 | -0.03 | -1.5% | $2.04 | $2.08 | $2.01 | 12,900 | |
| $2.04 | 0.00 | 0.0% | $2.025 | $2.08 | $2.016 | 8,719 | |
| $2.04 | +0.08 | +4.1% | $2.10 | $2.10 | $1.965 | 25,270 | |
| $1.96 | +0.01 | +0.5% | $1.98 | $2.10 | $1.952 | 15,200 | |
| $1.95 | -0.05 | -2.5% | $1.96 | $2.06 | $1.95 | 46,800 | |
| $2.00 | -0.08 | -3.8% | $2.09 | $2.09 | $2.00 | 10,800 | |
| $2.08 | +0.07 | +3.5% | $1.97 | $2.13 | $1.97 | 15,775 | |
| $2.01 | -0.08 | -3.8% | $2.08 | $2.20 | $2.00 | 1,018,110 | |
| $2.09 | -0.05 | -2.3% | $2.13 | $2.197 | $2.09 | 28,400 | |
| $2.14 | -0.05 | -2.3% | $2.19 | $2.298 | $2.14 | 76,300 | |
| $2.19 | -0.12 | -5.2% | $2.30 | $2.315 | $2.17 | 7,900 | |
| $2.31 | 0.00 | 0.0% | $2.28 | $2.43 | $2.16 | 23,800 | |
| $2.31 | +0.06 | +2.7% | $2.15 | $2.371 | $2.00 | 31,000 | |
| $2.25 | +0.03 | +1.4% | $2.20 | $2.29 | $2.087 | 65,100 | |
| $2.22 | +0.06 | +2.8% | $2.26 | $2.31 | $2.18 | 30,000 | |
| $2.16 | -0.19 | -8.1% | $2.35 | $2.35 | $2.16 | 21,500 | |
| $2.35 | -0.10 | -4.1% | $2.46 | $2.47 | $2.25 | 31,700 | |
| $2.45 | +0.23 | +10.4% | $2.35 | $2.55 | $2.28 | 74,400 | |
| $2.22 | -0.28 | -11.2% | $2.41 | $2.54 | $2.20 | 69,300 | |
| $2.50 | -0.07 | -2.7% | $2.55 | $2.58 | $2.36 | 68,800 | |
| $2.57 | +0.07 | +2.8% | $2.75 | $2.78 | $2.35 | 404,100 | |
| $2.50 | -0.23 | -8.4% | $2.75 | $2.75 | $2.475 | 42,300 | |
| $2.73 | +0.04 | +1.5% | $2.70 | $2.74 | $2.512 | 14,900 | |
| $2.69 | +0.07 | +2.7% | $2.68 | $2.69 | $2.575 | 18,000 | |
| $2.62 | +0.12 | +4.8% | $2.50 | $2.67 | $2.42 | 70,946 | |
| $2.50 | +0.08 | +3.3% | $2.40 | $2.54 | $2.38 | 32,637 | |
| $2.42 | -0.04 | -1.6% | $2.40 | $2.50 | $2.38 | 23,116 | |
| $2.46 | -0.06 | -2.4% | $2.52 | $2.53 | $2.41 | 33,800 | |
| $2.52 | -0.11 | -4.2% | $2.61 | $2.643 | $2.52 | 29,500 | |
| $2.63 | -0.07 | -2.6% | $2.67 | $2.70 | $2.56 | 15,500 | |
| $2.70 | +0.07 | +2.7% | $2.73 | $2.80 | $2.55 | 27,400 | |
| $2.63 | -0.24 | -8.4% | $2.77 | $2.855 | $2.63 | 36,100 | |
| $2.87 | +0.22 | +8.3% | $2.67 | $2.87 | $2.618 | 46,100 | |
| $2.65 | -0.07 | -2.6% | $2.64 | $2.695 | $2.56 | 24,800 |
Splits
1 split · AMEX:SER · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-35.7143 | Consolidation |
- Ticker
- NYSE American:SER
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 20 slides
Latest news
Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 12, 2026
Closed $1.39 (-1.4%) on Nov 13, 2026
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
Sep 9, 2026
Closed $2.57 (+2.8%) on Sep 9, 2026
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
Apr 7, 2026
Closed $2.08 (-3.3%) on Apr 7, 2026
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
Apr 2, 2026
Closed $2.15 (+1.4%) on Apr 6, 2026
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Mar 25, 2026
Closed $2.61 (-13.9%) on Mar 26, 2026
Serina Therapeutics to Present at the 38th Annual Roth Conference
Mar 24, 2026
Closed $2.43 (-22.9%) on Mar 24, 2026
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Mar 18, 2026
Closed $2.48 (+93.8%) on Mar 19, 2026
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Feb 24, 2026
Closed $1.77 (+6.0%) on Feb 25, 2026
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
Jan 28, 2026
Closed $3.54 (+30.1%) on Jan 29, 2026
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity
Jan 15, 2026
Closed $3.10 (+15.2%) on Jan 16, 2026
Serina Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 32 in all · newest Nov 12, 2026 · oldest 2025
- Decks
- 14 decks · latest September 2026
Where Serina Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:SER · Home listing · This page | NYSE American | United States | USD |
| Tradegate:2BO | Tradegate | Germany | EUR |
| BOATS:SER | BOATS | United States | USD |
| gettex:2BO | gettex | Germany | EUR |
| Lang & Schwarz:A407RQ | Lang & Schwarz | Germany | EUR |
| Frankfurt:2BO | Frankfurt | Germany | EUR |
Valuation
EV/sales 99.3× against a median of 1.2×: the highest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $12.42M USD
- P/E
- Loss
- EV/sales
- 99.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.0×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.60
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Serina Therapeutics, Inc. · AMEX:SER | US$28.45M | US$12.42M | n/a | 99.3× | n/a | 2.0× | n/a | 0.2× | 1.60 |
| NextCure, Inc. · NASDAQ:NXTC | US$29.53M | US$20.81M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.85 |
| NurExone Biologic Inc · TSXV:NRX | US$29.53M | US$28.52M | n/a | n/a | n/a | 23.3× | n/a | 0.0× | 0.00 |
| BioHarvest Sciences, Inc. · NASDAQ:BHST | US$29.47M | US$34.54M | n/a | 1.0× | n/a | 1.8× | −34.7% | 1.0× | 0.43 |
| Thiogenesis Therapeutics Corp · TSXV:TTI | US$29.28M | US$24.21M | n/a | n/a | n/a | 6.2× | n/a | 0.0× | 0.37 |
| NanoViricides, Inc. · AMEX:NNVC | US$29.11M | US$26.54M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.82 |
| Rein Therapeutics, Inc. · NASDAQ:RNTX | US$29.06M | −US$6.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 2.11 |
| Nicox SA · EURONEXT:ALCOX | US$29.05M | US$25.67M | n/a | 1.4× | n/a | 3.8× | −14.4% | 0.4× | n/a |
| ProMIS Neurosciences Inc. · NASDAQ:PMN | US$28.43M | −US$15.68M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.83 |
| Entropy Neurodynamics Limited · ASX:ENP | US$28.12M | US$24.43M | n/a | n/a | n/a | 5.8× | n/a | 0.0× | n/a |
| Holy Stone Healthcare Co., Ltd. · TPEX:4194 | US$27.49M | US$25.08M | n/a | n/a | n/a | 7.3× | n/a | 0.0× | n/a |
| Median of the others | US$29.09M | US$24.76M | 1.2× | 5.0× | −24.5% | 0.0× | 0.83 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.47 · 2 analysts
- Revenue, year to Dec 2026
- 125K · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Steve Ledger | CEO & Director |
| Greg Curhan | CFO |
| Joshua Thomas | VP, Head of Chemistry |
| Randall Moreadith | Chief Development Officer |
| Srini Tenjarla | Chief Technical Operations Officer |
Board
| Director | Role |
|---|---|
| Gregory Bailey | Co-Chairman |
| Simba Gill | Executive Co-Chairman |
| Farrell Simon | Director |
| Jay Venkatesan | Director |
| Karen J. Wilson | Director |
| Richard Marshall | Director |
| Steve Brannan | Director |
| Steve Ledger | CEO & Director |
Events
- Next results
- Nov 26, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 13, 2026 · After close | −1.8% |
| Q1 2026 | May 14, 2026 · After close | −4.7% |
| Q4 2025 | Mar 30, 2026 | −14.5% |
| Q3 2025 | Nov 13, 2025 · Before open | −2.5% |
| Q2 2025 | Aug 11, 2025 · After close | +7.1% |
| Q1 2025 | May 8, 2025 · After close | −2.0% |
| Q4 2024 | Mar 20, 2025 · Before open | +2.5% |
| Q3 2024 | Nov 11, 2024 · Before open | +20.9% |
| Q2 2024 | Aug 9, 2024 · After close | −10.1% |
| Q1 2024 | May 14, 2024 · After close | −4.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 22, 2024 · After close | −3.3% |
| Q4 2022 | Mar 31, 2023 | −1.4% |
| Q3 2022 | Nov 10, 2022 | −5.4% |
| Q2 2022 | Aug 12, 2022 | −0.3% |
| Q1 2022 | May 13, 2022 | +0.1% |
| Q4 2021 | Mar 29, 2022 | +6.8% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 | −1.1% |
| Quarter to Jun 30, 2021 | Aug 13, 2021 | −13.6% |
| Quarter to Mar 31, 2021 | May 17, 2021 | +2.5% |
| Quarter to Dec 31, 2020 | Mar 31, 2021 | +8.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 20 slides | September 2026 |
| Investor Presentation (July 2025) | Investor deck | 22 slides | Jul 29, 2025 |
| BTIG Small Molecule Platform Presentation (July 2025) | Conference | 21 slides | July 2025 |
| 4th LNP Formulation & Process Development Summit 2025 | Conference | 36 slides | Apr 15, 2025 |
| Investor Presentation (April 2025) | Investor deck | 26 slides | Apr 7, 2025 |
| ACS – Division of Polymer Chemistry (March 2025) | Conference | 36 slides | Mar 24, 2025 |
| Investor Presentation (January 2025) | Investor deck | 25 slides | Jan 6, 2025 |
| 3rd Immunogenicity & Toxicity Summit 2024 | Conference | 32 slides | Dec 11, 2024 |
| 14th Injectables Summit (October 2024) | Conference | 23 slides | Oct 2, 2024 |
| 4th mRNA-based Therapeutics Summit 2024 | Conference | 34 slides | Jul 29, 2024 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AgeX Therapeutics — Rodman & Renshaw Global Investment Conference 2019 | Conference | 33 slides | Sep 9, 2019 |
| 2nd Neuroscience Innovation Forum 2019 | Conference | 27 slides | Jan 6, 2019 |
| PODD 2016 | Conference | 16 slides | 2016 |
| Investor Presentation (April 2014) | Investor deck | 18 slides | April 2014 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$6 a share · JonesTrading Institutional Services LLC Dealers: JonesTrading Institutional Services LLC (lead) | Nov 13, 2025 |
| Financing agreement tranche Tranche closed: US$5M raised · US$5.18 a share · Warrants at US$5.44 Buyers: Greg Bailey, MD (leads the up to $20 million financing) Insiders: Financing led by Serina Board Director Greg Bailey, MD Use of proceeds: Advance the planned registrational trial of SER-252 for advanced Parkinson's disease | Oct 6, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.0K | 56.0K | 3.15M | 34.0K | 144.0K | 361.0K | 1.73M | 1.40M | 1.40M | 1.67M |
| Cost of revenue | 85.0K | 194.0K | 40.0K | 13.0K | 19.0K | 26.0K | 244.0K | 364.0K | 168.0K | 911.0K |
| Gross profit | 45.0K | -138.0K | 102.0K | 21.0K | 125.0K | 335.0K | 1.48M | 1.03M | 1.24M | 755.0K |
| Research and development | 13.2M | 7.48M | 2.39M | 1.02M | 1.46M | 3.71M | 5.90M | 5.83M | 5.78M | 7.87M |
| Selling, general and administrative | 11.0M | 9.62M | 3.89M | 1.29M | 1.30M | |||||
| Operating income | -24.0M | -17.0M | -3.13M | -6.97M | -7.93M | -10.1M | -12.6M | -11.2M | -6.66M | -12.7M |
| Depreciation and amortization | 100.0K | 100.0K | 90.0K | 61.3K | 33.4K | 699.0K | 393.0K | 58.0K | 165.0K | 845.0K |
| EBITDA | -23.9M | -16.9M | -3.04M | -6.91M | -7.90M | -9.40M | -12.2M | -11.2M | -6.50M | -11.9M |
| Interest expense | 213.0K | 526.0K | 4.90M | 3.33M | 1.10M | 404.0K | 12.0K | 25.0K | ||
| Income before tax | -19.2M | -11.2M | 5.27M | 10.5M | 8.70M | -11.1M | -12.2M | -7.73M | -6.64M | -17.4M |
| Income tax | 18.0K | 0 | 0 | -250.0K | 3.09K | -150.0K | 148.0K | -229.0K | -57.0K | -1.86M |
| Net income | -19.2M | -11.1M | 5.27M | -10.5M | -8.68M | -10.9M | -12.2M | -7.50M | -6.58M | -15.5M |
| Earnings per share, basic | -1.91 | -1.51 | 2.36 | -9.70 | -0.23 | -0.29 | -0.33 | -0.21 | -0.21 | -15.21 |
| Earnings per share, diluted | -1.91 | -1.51 | 0.73 | -9.70 | -0.23 | -0.29 | -0.33 | -0.21 | -0.21 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.06M | 3.67M | 7.62M | 645.0K | 584.0K | 527.0K | 2.35M | 6.71M | 7.38M | 259.0K |
| Short-term investments | 1.72M | 0 | 0 | 996.4K | ||||||
| Receivables | 57.0K | 4.00K | 25.0K | 326.0K | 363.0K | 131.0K | 107.0K | 308.0K | ||
| Inventory | -1.79M | -1.61M | ||||||||
| Current assets | 6.08M | 5.68M | 7.62M | 2.45M | 2.23M | 2.28M | 4.05M | 7.85M | 7.59M | 688.0K |
| Property, plant and equipment | 465.0K | 501.0K | 573.0K | 1.13M | 90.0K | 129.0K | ||||
| Total assets | 6.95M | 6.72M | 8.97M | 3.24M | 3.15M | 3.92M | 7.44M | 10.7M | 9.63M | 3.22M |
| Accounts payable | 1.93M | 744.0K | 580.0K | 568.0K | 193.0K | 761.0K | 420.0K | 150.0K | 75.0K | 261.0K |
| Current liabilities | 3.56M | 2.37M | 1.41M | 10.1M | 8.97M | 5.36M | 3.30M | 2.44M | 1.31M | 25.6M |
| Long-term debt | 2.95M | 0 | 2.98M | 1.62M | ||||||
| Total debt | 196.0K | 268.0K | 3.44M | 18.1M | 13.2M | 6.30M | 1.96M | |||
| Total liabilities | 6.99M | 6.22M | 4.86M | 20.6M | 15.0M | 9.32M | 4.83M | 2.44M | 1.31M | 25.6M |
| Shareholders' equity | -37.0K | 641.0K | -32.3M | -37.8M | -11.8M | -5.12M | 2.22M | 7.45M | 7.28M | -23.4M |
| Shares outstanding | 10.8M | 9.42M | 2.41M | 1.08M | 37.9M | 37.7M | 37.6M | 35.8M | 33.8M | 1.02M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -18.0M | -17.1M | -2.48M | -5.94M | -7.86M | -7.82M | -10.2M | -8.00M | -6.29M | -8.43M |
| Capital spending | -59.0K | -22.0K | -504.0K | -9.68K | -108.4K | -20.0K | -641.0K | -21.0K | -1.00K | -23.0K |
| Free cash flow | -18.0M | -17.2M | -2.98M | -2.09M | -2.36M | -7.84M | -10.8M | -8.02M | -6.29M | -8.45M |
| Cash from investing | -59.0K | -22.0K | -504.0K | 980.9K | 666.0K | -20.0K | -361.0K | 1.33M | 5.00K | -28.0K |
| Cash from financing | 17.4M | 13.2M | 10.1M | 6.00M | 7.25M | 5.96M | 6.26M | 6.00M | 13.3M | 7.25M |
| Share buybacks | 12.5M | 10.0M | 0 | |||||||
| Change in cash | -616.0K | -3.95M | 7.09M | 61.0K | 57.0K | -1.88M | -4.25M | -668.0K | 7.12M | -1.20M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 3, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 9, 2026 | Current report | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 1, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 26, 2026 | Material contract | SEC |
| S-1 · Registration statement | Aug 24, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 13, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 23, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 23, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 22, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 4, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 1, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| S-3 · Registration statement | May 22, 2026 | Offer document | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 4, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Mar 27, 2026 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 25, 2026 | Results | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 23, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Feb 17, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 11, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Jan 30, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| DEFR14A | Oct 27, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 6, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Sep 26, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 26, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 15, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2025 | Current report | SEC |
| 8-K · Current report | Aug 22, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 29, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 30, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2025 | Insider trade | SEC |
| 8-K · Current report | May 22, 2025 | Management or board change | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 29, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Apr 25, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 23, 2025 | Other filings | SEC |
| S-3 · Registration statement | Apr 17, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| 8-K · Current report | Apr 14, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Apr 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 7, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Apr 2, 2025 | Offer document | SEC |
| S-3 · Registration statement | Apr 2, 2025 | Offer document | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Mar 25, 2025 | Offer document | SEC |
| POS EX | Mar 24, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 24, 2025 | Results | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2025 | Management or board change | SEC |
| 8-K · Current report | Feb 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2025 | Management or board change | SEC |
| 8-K · Current report | Jan 6, 2025 | Results | SEC |
| 8-K · Current report | Dec 23, 2024 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 9, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 2, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Nov 22, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Nov 6, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Nov 6, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 6, 2024 | Meeting notice | SEC |
| DEFC14A | Nov 1, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 2, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 12, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 4, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 23, 2024 | Offer document | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 15, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2024 | Current report | SEC |
| 8-K · Current report | Jul 18, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 12, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jul 10, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 5, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Jul 5, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 3, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| S-1/A · Registration statement, amended | Jun 14, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jun 14, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 10, 2024 | Current report | SEC |
This page holds 200 of 521 filings. Open Filings
Cap table
Built by 6ix from Serina Therapeutics, Inc.’s releases · as of Nov 13, 2025
- Common shares
- 25,400,473
- Fully diluted
- 25,400,473
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 25,400,473 |
Warrants and options
| Lot |
|---|
| Warrants · US$5.44 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 25,400,473 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Annalisa Jenkins Other companies: Skye Bioscience, Inc. (Director · Since at least Feb 29, 2024); Mereo BioPharma Group plc (Director · Since at least Jan 1, 2024); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Dimension Therapeutics (President and CEO, Director · Oct 21, 2015 – Nov 7, 2017 · Past); Ardelyx, Inc. (Director · Apr 20, 2015 – Jun 13, 2019 · Past) | Director · Nov 27, 2018 – Jun 21, 2021 · Past |
| Russell Skibsted Other companies: Processa Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jul 16, 2024); Aeolus Pharmaceuticals Inc (Chief Financial Officer · Since at least May 23, 2012); Alimera Sciences Inc (Chief Financial Officer & SVP · Jan 9, 2023 – Nov 21, 2023 · Past); Rockwell Medical, Inc. (See Remarks · Sep 15, 2020 – Sep 9, 2022 · Past); Insight Molecular Diagnostics Inc. (Chief Financial Officer · Dec 30, 2015 – Dec 30, 2015 · Past); Lineage Cell Therapeutics, Inc. (Chief Financial Officer · Nov 16, 2015 – Dec 18, 2018 · Past) | Chief Financial Officer · Nov 27, 2018 – Dec 31, 2018 · Past |
| Karen J. Wilson Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Mar 16, 2026); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Elicio Therapeutics, Inc. (Director · Since at least Feb 4, 2021); Vaxart, Inc. (Director · Aug 25, 2020 – Jun 16, 2021 · Past); Jazz Pharmaceuticals plc (SVP, Finance & PAO · Mar 9, 2011 – Mar 5, 2019 · Past) | Director · Since at least Jan 14, 2025 |
| Jay Venkatesan Other companies: Elicio Therapeutics, Inc. (Director · Since at least May 20, 2022); Alpine Immune Sciences Inc (Director · Jul 15, 2022 – Jul 15, 2022 · Past) | Director · Since at least Feb 12, 2025 |
| Michael H. Mulroy Other companies: Lineage Cell Therapeutics, Inc. (Chairman of the Board · Since at least Jul 1, 2016); Asterias Biotherapeutics Inc (President and CEO, Director · Jun 26, 2017 – Mar 1, 2019 · Past) | Director · Nov 27, 2018 – Mar 11, 2019 · Past |
| Andrea Eun Jae Park | Chief Financial Officer · Jun 4, 2021 – Jun 4, 2021 · Past |
| Farrell Simon | Director · Since at least Nov 5, 2026 |
| Greg Curhan | CFO · Since at least Nov 4, 2026 |
| Gregory Bailey | Co-Chairman · Since at least Jun 22, 2026 |
| Joanne M Hackett | Director · Dec 29, 2021 – Feb 2, 2022 · Past |
All 21 people
| Person | Seat |
|---|---|
| Joshua Thomas | VP, Head of Chemistry · Since at least Dec 11, 2025 |
| Randall Moreadith | Chief Development Officer · Since at least Mar 26, 2024 |
| Remy Gross | Director · Mar 26, 2024 – Apr 1, 2024 · Past |
| Richard Marshall | Director · Since at least Mar 26, 2024 |
| Simba Gill | Executive Co-Chairman · Since at least Mar 25, 2026 |
| Srini Tenjarla | Chief Technical Operations Officer · Since at least Nov 4, 2026 |
| Stephen K Brannan | Director · Since at least Jul 7, 2026 |
| Steve Brannan | Director · Since at least May 22, 2025 |
| Steve Ledger | CEO & Director · Since at least May 27, 2026 |
| Steven A Ledger | Chief Executive Officer, Director · Since at least Mar 26, 2024 |
| Tacey Viegas | COO and Secretary · Mar 26, 2024 – Mar 26, 2024 · Past |
Log in to ask 6ix AI your own questions about Serina Therapeutics, Inc.